NOVO NORDISK A/S

NYSE: NVO (Novo Nordisk A/S)

最近更新时间: 01 Aug, 11:46PM

48.19

1.12 (2.38%)

  • 1天 2.38%
  • 5天 -12.75%
  • 1月 -8.05%
  • 6月 -39.88%
  • 今年至今天 -44.94%
  • 1年 -64.80%
  • 5年 41.90%
前收盘价格 47.07
收盘价格 48.27
成交量 34,693,939
平均成交量 (3个月) 12,924,509
市值 213,983,363,072
市盈率 (P/E TTM) 13.42
预期市盈率 (P/E Forward) 13.09
价格/销量 (P/S) 5.00
股市价格/股市净资产 (P/B) 9.25
52周波幅
46.90 (-2%) — 139.74 (189%)
利润日期 6 Aug 2025
股息率 (DY TTM) 2.28%
营业毛利率 34.51%
营业利益率 (TTM) 49.68%
稀释每股收益 (EPS TTM) 3.67
季度收入增长率 (YOY) 19.50%
季度盈利增长率 (YOY) 14.30%
总债务/股东权益 (D/E MRQ) 85.70%
流动比率 (MRQ) 0.740
营业现金流 (OCF TTM) 131.24 B
杠杆自由现金流 (LFCF TTM) 77.73 B
资产报酬率 (ROA TTM) 23.29%
股东权益报酬率 (ROE TTM) 88.12%

市场趋势

短期 中期
行业 Drug Manufacturers - General (US) 混合的 看跌
Drug Manufacturers - General (全球的) 混合的 看跌
股票 Novo Nordisk A/S 看涨 看跌

AIStockmoo 评分

1.6
分析师共识 1.5
内部交易活动 NA
价格波动 4.5
技术平均移动指标 0.0
技术振荡指标 0.5
平均 1.63

相关股票

股票 市值 DY P/E（TTM） P/B
NVO 214 B 2.28% 13.42 9.25
LLY 668 B 0.38% 48.62 37.07
NVS 245 B 3.23% 18.46 5.72
MRK 210 B 2.84% 12.97 4.22
JNJ 427 B 1.40% 18.97 5.48
ABBV 386 B 2.21% 103.97 50.46

With roughly one-third of the global branded diabetes treatment market, Novo Nordisk is the leading provider of diabetes care products in the world. Based in Denmark, the company manufactures and markets a variety of human and modern insulins, injectable diabetes treatments such as GLP-1 therapy, oral antidiabetic agents, and obesity treatments. Novo also has a biopharmaceutical segment (contributing less than 10% of revenue) that specializes in protein therapies for hemophilia and other disorders.
部门 Healthcare
行业 Drug Manufacturers - General
投资方式 Large Growth
内部持股比例 0.01%
机构持股比例 9.85%

所有权

姓名 日期 持有股份
Everett Harris & Co /Ca/ 31 Mar 2025 6,408,022
52周波幅
46.90 (-2%) — 139.74 (189%)
中 70.00 (45.26%)
总计 1 购买
公司 日期 目标价格 调整类型 价格@调整类型
TD Cowen 19 Aug 2025 70.00 (45.26%) 购买 54.78

该时间范围内无数据。

  • 3M
日期 类型 细节
15 Sep 2025 公告 EU approval makes Novo Nordisk’s oral semaglutide the first and only oral GLP-1 RA to reduce cardiovascular death, heart attack and stroke
12 Sep 2025 CNBC Eli Lilly, Novo Nordisk prepare to face off in the next obesity drug battleground
11 Sep 2025 CNBC Health care inflation rises as patients, employers brace for biggest jump in health spending in 15 years
10 Sep 2025 公告 Novo Nordisk to streamline operations and reinvest for growth
05 Sep 2025 公告 Novo Nordisk to present new semaglutide data on ‘food noise’, body composition and cardiovascular benefits, as well as pipeline data at the EASD diabetes congress
05 Sep 2025 公告 Investors SueWallSt as Novo Nordisk A/S Faces Securities Fraud Allegations
03 Sep 2025 公告 Shareholders SueWallSt in New Class Action Against Novo Nordisk A/S - Act Now
31 Aug 2025 公告 Novo Nordisk’s Wegovy® cuts risk of heart attack, stroke or death by 57% compared to tirzepatide in real-world study of people with obesity and cardiovascular diseas
26 Aug 2025 CNBC Eli Lilly’s weight loss pill orforglipron clears its latest trial, paving way for approval
24 Aug 2025 CNBC Eli Lilly's obesity pill remains a viable rival to Novo's oral Wegovy despite data that underwhelmed investors
21 Aug 2025 CNBC FDA approves first-ever glucose monitoring system for weight loss from Signos 
20 Aug 2025 公告 Novo Nordisk to present Wegovy® and Ozempic® data showing life-saving cardiovascular benefits for people living with obesity and type 2 diabetes at the European Society of Cardiology Congress 2025
19 Aug 2025 CNBC Viking Therapeutics shares fall 40% on disappointing obesity pill trial data
19 Aug 2025 公告 BioMed X and Novo Nordisk Launch New Collaboration in Oral Peptide Drug Delivery
18 Aug 2025 CNBC Novo Nordisk offers diabetes drug Ozempic for less than half the price for cash-paying U.S. patients
15 Aug 2025 公告 Novo Nordisk A/S: Wegovy® approved in the US for the treatment of MASH
15 Aug 2025 公告 Wegovy® approved by FDA for the treatment of adults with noncirrhotic MASH with moderate to advanced liver fibrosis
07 Aug 2025 CNBC Eli Lilly shares drop after obesity pill shows modest late-stage trial results
06 Aug 2025 公告 Novo Nordisk's sales increased by 16% in Danish kroner and by 18% at constant exchange rates to DKK 154.9 billion in the first six months of 2025
31 Jul 2025 CNBC Eli Lilly’s Mounjaro shows heart health benefits in head-to-head trial with older diabetes drug Trulicity
31 Jul 2025 CNBC Trump says he asked 17 drugmakers to take steps to cut U.S. prices within 60 days
29 Jul 2025 公告 Maziar Mike Doustdar appointed as president and chief executive officer of Novo Nordisk
29 Jul 2025 公告 Novo Nordisk lowers sales and operating profit outlook for 2025
25 Jul 2025 公告 European regulatory authority adopts positive opinion for Novo Nordisk’s Alhemo® (concizumab), recommending label expansion to treat haemophilia A and B without inhibitors
21 Jul 2025 CNBC Weight loss drugs could be a gamechanger for women with a common hormonal disorder
09 Jul 2025 CNBC Hims & Hers to offer generic semaglutide in Canada as Novo Nordisk patent lapses
28 Jun 2025 公告 HIMS INVESTOR NOTICE: Hims & Hers Health, Inc. Investors with Substantial Losses Have Opportunity to Lead Class Action Lawsuit
26 Jun 2025 公告 Novo Nordisk continues efforts to support patient access to authentic, FDA approved Wegovy® and prioritize patient safety
23 Jun 2025 公告 Novo Nordisk A/S: Ozempic® receives EU recommendation in peripheral arterial disease, cementing the broad benefits of semaglutide for people with type 2 diabetes and comorbidities
23 Jun 2025 公告 Novo Nordisk terminates collaboration with Hims & Hers Health, Inc. due to concerns about their illegal mass compounding and deceptive marketing
23 Jun 2025 CNBC Novo Nordisk ends deal with Hims & Hers over sales of Wegovy copycats; HIMS drops 34%
22 Jun 2025 公告 Novo Nordisk A/S: CagriSema 2.4 mg / 2.4 mg demonstrated 22.7% mean weight reduction in adults with overweight or obesity in REDEFINE 1, published in New England Journal of Medicine
22 Jun 2025 公告 Novo Nordisk A/S: Mim8 prophylaxis treatment shown to be well-tolerated when switching from emicizumab in people with haemophilia A in new phase 3 data presented at the ISTH 2025 Congress
20 Jun 2025 公告 Novo Nordisk’s subcutaneous and oral amycretin data published in The Lancet and presented at ADA 2025
20 Jun 2025 公告 Novo Nordisk: Higher dose of Wegovy® provided average weight loss of 21% in people with obesity – with a third achieving 25% or more – according to data presented at ADA
显示更多
股息率 (DY TTM) 2.28%
5年平均股息收益率 2.48%
股息支付比率 47.09%
预计下次股息支付 Apr 2026
除息日 公告日期 支付日期 详情
31 Mar 2025 05 Feb 2025 08 Apr 2025 1.099206 现金
16 Aug 2024 06 Aug 2024 26 Aug 2024 0.5126402 现金
22 Mar 2024 31 Jan 2024 02 Apr 2024 0.92985 现金
18 Aug 2023 10 Aug 2023 29 Aug 2023 0.8835613 现金
24 Mar 2023 02 Feb 2023 04 Apr 2023 1.1887415 现金
12 Aug 2022 04 Aug 2022 23 Aug 2022 0.5835507 现金
25 Mar 2022 02 Mar 2022 05 Apr 2022 1.022423 现金
16 Aug 2021 - 25 Aug 2021 0.5502889 现金
26 Mar 2021 - 07 Apr 2021 0.922122 现金
14 Aug 2020 06 Aug 2020 25 Aug 2020 0.5177774 现金
27 Mar 2020 06 Feb 2020 07 Apr 2020 0.7826048 现金
16 Aug 2019 10 Aug 2019 27 Aug 2019 0.449438 现金
22 Mar 2019 05 Feb 2019 02 Apr 2019 0.777006 现金
17 Aug 2018 09 Aug 2018 28 Aug 2018 0.462327 现金
23 Mar 2018 24 Mar 2018 03 Apr 2018 0.805982 现金
17 Aug 2017 - 29 Aug 2017 0.33589 现金
23 Mar 2017 - 04 Apr 2017 0.479369 现金
11 Aug 2016 - 23 Aug 2016 0.331026 现金
18 Mar 2016 - 30 Mar 2016 0.69943 现金
19 Mar 2015 - 31 Mar 2015 0.532885 现金
21 Mar 2014 - 02 Apr 2014 0.606122 现金
21 Mar 2013 - 02 Apr 2013 2.264307 现金
22 Mar 2012 - 03 Apr 2012 1.831902 现金
24 Mar 2011 - 05 Apr 2011 1.357901 现金
25 Mar 2010 - 07 Apr 2010 0.978615 现金
19 Mar 2009 - 31 Mar 2009 0.781532 现金
13 Mar 2008 - 25 Mar 2008 0.678462 现金
08 Mar 2007 - 20 Mar 2007 0.891779 现金
09 Mar 2006 - 21 Mar 2006 0.691753 现金
10 Mar 2005 - 22 Mar 2005 0.61725 现金
17 Mar 2004 - 29 Mar 2004 0.52096 现金
26 Mar 2003 - 07 Apr 2003 0.37647 现金
13 Mar 2002 - 25 Mar 2002 0.2848 现金
21 Mar 2001 - 02 Apr 2001 0.5681 现金
24 Mar 2000 - 06 Apr 2000 0.4672 现金
25 Mar 1999 - 06 Apr 1999 0.4182 现金
27 Mar 1998 - 08 Apr 1998 0.3051 现金
25 Apr 1997 - 07 May 1997 0.239 现金
01 May 1996 - 14 May 1996 0.1806 现金
显示更多

每年股息收益率

年份 每年总股息 ($) 频率/年份 收益率 %
2025 1.10 1 2.28
2024 1.44 2 1.68
2023 2.07 2 2.00
2022 1.61 2 2.37
2021 1.47 2 2.63
2020 1.30 2 3.72
2019 1.23 2 4.24
2018 1.27 2 5.51
2017 0.815 2 3.04
2016 1.03 2 5.75
2015 0.533 1 1.84
2014 0.606 1 2.86
2013 2.26 1 12.26
2012 1.83 1 11.22
2011 1.36 1 11.78
2010 0.979 1 8.69
2009 0.782 1 12.24
2008 0.678 1 13.20
2007 0.892 1 13.75
2006 0.692 1 16.54
2005 0.617 1 21.94
2004 0.521 1 19.20
2003 0.376 1 18.38
2002 0.285 1 19.71
2001 0.568 1 28.33
2000 0.467 1 26.40
1999 0.418 1 32.36
1998 0.305 1 22.94
1997 0.239 1 16.57
1996 0.181 1 19.32
显示更多

支撑、阻力和趋势线水平是由人工智能（AI）模型生成的，请谨慎解读。

投资组合

AI 建议策略模板

自定义的价格提醒

风险概况

| | | | |
很保守
适度保守
中等
中等风险
激进风险
安全边际 (EP)
部分利润 (TP1)
目标利润 (TP2)
最大损失 (SL)

免责声明：以上内容仅供参考，并非投资建议。请咨询合格的财务顾问。

开始购买价格 (EP)

第一个目标价格赚取利润 (TP1)

第二个目标价格赚取利润 (TP2)

停止损失价格 (SL)

52周波幅范围
 
52WL
 
52WH
SL
EP
TP1
TP2

所有提醒价格都在52周波幅范围内

已实现利润 -
未实现利润 -
收到股息 2025 -
利润总额 -
平均回报 -
数量(购买) -
平均价格(购买) -
数量(卖出) -
平均价格(卖出) -
没有符合您标准的股票